| Date Filed | Type | Description |
| 08/18/2022 |
REVOKED
| Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]: |
| 04/13/2021 |
8-K
| Quarterly results |
| 04/12/2021 |
8-K
| Quarterly results |
| 02/04/2020 |
4
| Fiorino Anthony S. (Director) has filed a Form 4 on IMMUNE PHARMACEUTICALS INC|
Txns:
| Sold 75,000 shares
@ $0.0035, valued at
$262.5 |
|
| 08/12/2019 |
SC 13G
| Hughes Eric Olan reports a 6.2% stake in Immune Pharmaceuticals Inc. |
| 03/08/2019 |
8-K
| Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...|
Docs:
|
"EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is entered into as of March 7, 2019, by and between Gary H. Rabin , and Immune Pharmaceuticals Inc . Company desires to engage Rabin as President and Interim Chief Executive Officerto provide certain services to Company as more particularly set forth in Exhibit A attached hereto and made a part hereof . The parties desire to set forth, in writing, the terms and conditions concerning the engagement. Accordingly, in consideration of the mutual covenants in this Agreement, and for other good and valuable consideration, it is agreed as follows: 1. Engagement and Commencement Date. Commencing on March 7, 2019 , Company hereby engages Rabin as President and Interim Chief Executive Officer, on the terms and conditions set forth in this Agreement. By ...",
"Investor Contact" |
|
| 02/14/2019 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 02/07/2019 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 01/17/2019 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/08/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/19/2018 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 12/19/2018 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 12/06/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/06/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/28/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/26/2018 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 11/21/2018 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/20/2018 |
3
| Clark John P (See Remarks) has filed a Form 3 on IMMUNE PHARMACEUTICALS INC |
| 11/14/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/08/2018 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/29/2018 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/22/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 10/10/2018 |
8-K
| Quarterly results |
| 09/18/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 09/10/2018 |
8-K
| Resignation/termination of a director |
| 08/14/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 07/26/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 07/26/2018 |
GN
| Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018 |
| 07/17/2018 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/17/2018 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/17/2018 |
GN
| Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split |
| 06/29/2018 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/08/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 06/08/2018 |
GN
| Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination |
|